We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+124.18%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$628M
Cap. Flow
+$47.5M
Cap. Flow %
2.9%
Top 10 Hldgs %
56.65%
Holding
43
New
13
Increased
12
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$67.8M
2
EXAS
Exact Sciences
EXAS
+$51M
3
AXGN icon
Axogen
AXGN
+$44.1M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$34.7M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$96.9M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$94.9M
3
GMED icon
Globus Medical
GMED
+$67.1M
4
VCEL icon
Vericel Corp
VCEL
+$35.5M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$29.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
1
Aurinia Pharmaceuticals
AUPH
$1.97B
$134M 8.19%
6,625,671
+4,064,402
+159% +$37.4M
ARQL
2
DELISTED
Arqule Inc
ARQL
$134M 8.18%
6,715,965
+2,704,623
+67% +$31.4M
KPTI icon
3
Karyopharm Therapeutics
KPTI
$168M
$117M 7.17%
408,496
+19,334
+5% +$4.19M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$106M 6.47%
4,306,575
+331,521
+8% +$4.92M
UTHR icon
5
United Therapeutics
UTHR
$26.3B
$81M 4.94%
919,263
-48,306
-5% -$4.25M
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$75.2M 4.59%
1,901,667
+235,000
+14% +$4.13M
ALGN icon
7
Align Technology
ALGN
$12B
$75.1M 4.58%
269,000
-30,000
-10% -$7.48M
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
$70.9M 4.32%
15,642,064
+4,948,490
+46% +$18.1M
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$67.8M 4.14%
1,975,000
+1,955,000
+9,775% +$23.5M
QURE icon
10
uniQure
QURE
$2.68B
$66.6M 4.06%
929,036
-499,166
-35% -$27.4M
GWPH
11
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$63.2M 3.86%
+604,604
New +$67.8M
EXAS
12
DELISTED
Exact Sciences
EXAS
$53.6M 3.27%
+579,666
New +$51M
AXGN icon
13
Axogen
AXGN
$2.1B
$53.4M 3.26%
+2,986,386
New +$44.1M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.66B
$46M 2.8%
356,145
+344,145
+2,868% +$34.7M
CDNA icon
15
CareDx
CDNA
$1.92B
$45.8M 2.79%
2,121,976
+1,395,848
+192% +$32M
OMER icon
16
Omeros
OMER
$709M
$45M 2.75%
3,195,796
+364,687
+13% +$5.34M
IOVA icon
17
Iovance Biotherapeutics
IOVA
$2.23B
$41.8M 2.55%
1,509,327
-170,000
-10% -$3.87M
OXFD
18
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$39.2M 2.39%
2,363,724
+219,200
+10% +$3.55M
ASMB icon
19
Assembly Biosciences
ASMB
$506M
$38.4M 2.35%
+156,533
New +$28.8M
TVTX icon
20
Travere Therapeutics
TVTX
$5.33B
$32.9M 2.01%
2,314,421
– –
TNDM icon
21
Tandem Diabetes Care
TNDM
$1.17B
$32.8M 2%
550,956
-471,301
-46% -$29.1M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$29.4M 1.79%
+3,426,365
New +$12.2M
LMNL
23
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$27.5M 1.68%
+328,731
New +$22.2M
VCEL icon
24
Vericel Corp
VCEL
$2.3B
$27.1M 1.65%
1,556,137
-2,088,355
-57% -$35.5M
APTO
25
DELISTED
Aptose Biosciences, Inc.
APTO
$27.1M 1.65%
+10,605
New +$13.8M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Consonance Capital Management held 43 positions worth $1.64B, up 62% from $1.01B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Consonance Capital Management's Q4 2019 filing shows 13 new, 12 increased, 8 reduced and 8 closed positions. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 604,604 shares worth $63.2M. The largest sale was Amarin Corp, an estimated $96.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 99% a quarter earlier.

  • Consonance Capital Management's largest Q4 2019 buy was GW Pharmaceuticals Plc American Depositary Shares: 604,604 shares worth $63.2M.
  • Consonance Capital Management added most to Aurinia Pharmaceuticals in Q4 2019, an estimated $37.4M increase.
  • Consonance Capital Management's biggest Q4 2019 reduction was Vericel Corp, cutting an estimated $35.5M.
  • Consonance Capital Management fully exited Amarin Corp in Q4 2019, selling an estimated $96.9M.
  • Consonance Capital Management's ten largest holdings make up 57% of its $1.64B portfolio in Q4 2019.
  • Consonance Capital Management opened 13 new positions and closed 8 in Q4 2019.
  • Consonance Capital Management's portfolio value rose 62% quarter-over-quarter to $1.64B.

Based on Consonance Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.